SMS Mobile Technology for Vaccine Coverage and Acceptance
Launched by UNIVERSITY OF COLORADO, DENVER · Aug 8, 2012
Trial Information
Current as of June 15, 2025
Completed
Keywords
ClinConnect Summary
Significance: Vaccine coverage and acceptance in many municipal districts of Guatemala and other low- and middle-income countries are below the acceptable 80% reported at the national level for DPT3 (diphtheria, pertussis, tetanus) and measles vaccines. Despite the considerable effort to introduce new vaccines like Hib (Haemophilus influenzae type B) and rotavirus, in many countries like Guatemala infants do not get immunized on time. Completion of the recommended primary series does not reach beyond 70% of eligible infants by 12 months of age, placing them at risk of disease due to incompl...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Infants 1-3 months of age coming for their 1 dose of primary vaccines
- Exclusion Criteria:
- • Received 1 dose of vaccines, excluding BCG
- • No mobile phone with SMS or unable to use SMS at home
- • Intent to move from the clinic area in the next 6 months
About University Of Colorado, Denver
The University of Colorado, Denver, is a leading academic institution dedicated to advancing medical research and improving healthcare outcomes. With a strong emphasis on innovation and collaboration, the university conducts a diverse range of clinical trials aimed at addressing critical health challenges. Its research initiatives are supported by a multidisciplinary team of experts, state-of-the-art facilities, and a commitment to ethical standards and patient safety. By fostering partnerships with local and global communities, the University of Colorado, Denver, strives to translate scientific discoveries into meaningful advancements in clinical practice and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guatemala, , Guatemala
Patients applied
Trial Officials
Edwin J Asturias, MD
Principal Investigator
University of Colorado School of Medicine
Ingrid L Contreras-Roldan, MD
Study Director
University del Valle, Guatemala
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials